[Comparison of the absorbed dose at calibration depth of photon beams using the Japan Society of Medical Physics 12 beam quality conversion factor in the presence or absence of a waterproofing sleeve].

In standard external beam radiotherapy dosimetry, which is based on absorbed dose by water, the absorbed dose at any calibration depth is calculated using the same beam quality conversion factor, regardless of the presence or absence of a waterproofing sleeve. In this study, we evaluated whether there were differences between absorbed doses at calibration depths calculated using a beam quality conversion factor including a wall correction factor that corresponds to a waterproofing sleeve thickness of 0.3 mm, and without a waterproofing sleeve. The Japan Society of Medical Physics (JSMP) has reported that the uncertainty of the results using a beam quality conversion factor that included a wall correction factor corresponding to a waterproofing sleeve thickness of 0.3 mm, regardless of the presence or absence of the sleeve, was 0.2%. This uncertainty proved to be in agreement with the reported range.

[A comparison of absorbed doses to water in photon beams in Japan Society of Medical Physics 01 and 12].

A comparison of absorbed doses to water at a calibration depth determined by Japan Society of Medical Physics (JSMP) 12 and 01 was conducted, using a farmer type ionization chamber. The absorbed dose to water calibration factor (ND,W,Q0) and beam quality conversion factor (kQ,Q0) for JSMP 12 were smaller than the absorbed dose to water calibration factor and beam quality conversion factor for JSMP 01. Differences in absorbed doses at a calibration depth were -0.78% for 6 MV photon beam and -0.94% for 10 MV photon beam. In the present experiment, absorbed doses at a calibration depth were measured, using a farmer type ionization chamber. Further experiments at a larger number of facilities should be conducted to reveal the status of measurement of absorbed doses at a calibration depth using JSMP 12.

Diversity of aspartate carbamoyltransferase genes of Trypanosoma cruzi.

The pyrimidine-biosynthetic (pyr) gene cluster, a tandem array of pyr1-pyr3-pyr6/5-pyr2(ACT)-pyr4 from the 5' terminus, encodes all the six enzymes of de novo pyrimidine biosynthesis and occurs as a polycistronic transcription unit in Trypanosoma cruzi. The gene encoding aspartate carbamoyltransferase (ACT), the second enzyme of the pathway, was characterised using a laboratory-reared Tulahuen strain and Tulahuen-derived clones of T. cruzi. Three loci with different restriction maps that contain ACT1, ACT2, and ACT3 were identified. ACT1 and ACT2 are involved in the pyr gene cluster on two different chromosomal DNA molecules of 1,000 and 800 kb, respectively, whereas ACT3 is linked with pyr4 alone. There are 29 nucleotide substitutions out of 981 positions in these three ACTs, yielding 13 amino acid replacements, and a deletion of triplet nucleotides in ACT1 entails a lack of single amino acid residue. Transcription of the three ACTs takes place in the three developmental stages of the parasite, epimastigotes, trypomastigotes, and amastigotes. Pulsed field gel electrophoresis and Southern blot analyses demonstrated that the cloned T. cruzi stocks, Y-02, CAN III/1, Sylvio-X10/4, and possibly Esmeraldo/3, also possess two complete sets of the pyr gene cluster including ACT, accompanied by additional incomplete clusters. These results suggest that the marked intra-species diversity in the copy number and chromosomal localisations of ACT and other pyr genes may have resulted from partial duplications and subsequent translocations of the polycistronic pyr gene cluster.